XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Additional Information (Details)
£ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
GBP (£)
Other Commitments [Line Items]          
Research and development expense $ 7,960,000 $ 7,218,000 $ 24,060,000 $ 19,548,000  
Alloy Therapeutics Llc [Member]          
Other Commitments [Line Items]          
Payment of annual license fees and program fees     100,000    
Research and development expense 50,000 50,000 100,000 50,000  
Alloy Therapeutics Llc [Member] | Development Milestone [Member] | First Selected Antibody [Member] | Maximum [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 1,800,000   1,800,000    
Alloy Therapeutics Llc [Member] | Development Milestone [Member] | Second Selected Antibody [Member] | Maximum [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 3,100,000   3,100,000    
Alloy Therapeutics Llc [Member] | Commercial Milestone [Member] | First Selected Antibody [Member] | Maximum [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 11,000,000   11,000,000    
Alloy Therapeutics Llc [Member] | Commercial Milestone [Member] | Second Selected Antibody [Member] | Maximum [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 15,000,000   15,000,000    
Ligand Pharmaceuticals Incorporated [Member]          
Other Commitments [Line Items]          
Research and development expense   100,000 200,000 100,000  
Ligand Pharmaceuticals Incorporated [Member] | Development Milestone [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 12,200,000   12,200,000    
Ligand Pharmaceuticals Incorporated [Member] | Commercial Milestone [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 0   0    
IONTAS Limited [Member]          
Other Commitments [Line Items]          
Research and development expense 600,000 $ 200,000 2,000,000 $ 800,000  
IONTAS Limited [Member] | Development Milestone [Member] | First Development Program [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 3,900,000   3,900,000   £ 3.1
IONTAS Limited [Member] | Development Milestone [Member] | Second Development Program [Member]          
Other Commitments [Line Items]          
Potential milestone payments due 3,100,000   3,100,000   2.5
IONTAS Limited [Member] | Commercial Milestone [Member] | First Development Program [Member]          
Other Commitments [Line Items]          
Potential milestone payments due $ 2,900,000   $ 2,900,000   £ 2.3